Pacific Biosciences of Californ (PACB)

Pacific Biosciences of Californ's Q·Score is 5.5/10 (Neutral), reflecting its current fundamentals, analyst data, and valuation metrics. Revenue expanding at 14% year-over-year. Key area to monitor: low return on equity (-213%). This is an informational data summary only and does not constitute financial advice. Always do your own research before making any investment decision.

The consensus price target for PACB is $2.38, based on ratings from 6 Wall Street analysts. This is 48.4% above the current price of $1.60. Price targets are forward-looking estimates and not guarantees of future performance.

Pacific Biosciences of Californ (PACB) scores in line with sector averages on valuation metrics. The consensus analyst price target of $2.38 is 48% above the current price.

Pacific Biosciences of Californ is scheduled to report earnings in 4 days, on May 7, 2026.

Pacific Biosciences of Californ has a net profit margin of 0.0%, indicating the company is currently operating at a net loss. Its gross margin stands at 34.3%, reflecting a more cost-intensive business model.

Pacific Biosciences of Californ is reporting solid revenue growth of 13.8% year-over-year.

Pacific Biosciences of Californ has a debt-to-equity ratio of 131.32×, reflecting a high debt-to-equity ratio, which increases financial risk especially in rising rate environments. Its current ratio is 5.15×, indicating comfortable short-term liquidity.